gmp
gmp

Find Clinical Drug Pipelines for Nutrition and Weight Loss

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Miricorilant

            Therapeutic Area: Nutrition and Weight Loss Product Name: CORT118335

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 10, 2020

            Details:

            GRATITUDE I, Corcept’s first Phase 2 trial of miricorilant in APIWG, continues to enroll patients with schizophrenia and recent weight gain.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Deoxycholic Acid

            Therapeutic Area: Nutrition and Weight Loss Product Name: Kybella

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: SWK Holdings Corporation

            Deal Size: $4.3 million Upfront Cash: $4.3 million

            Deal Type: Divestment August 31, 2020

            Details:

            Under the terms of the definitive agreement, PDL BioPharma will sale three royalty interests for Kybella®, Zalviso®, and Coflex® (collectively the "Royalties") to SWK Funding, LLC a wholly owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tesofensine,Metoprolol Tartrate

            Therapeutic Area: Nutrition and Weight Loss Product Name: Tesomet

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 24, 2020

            Details:

            The poster to be presented will highlight the results from a phase 2 clinical trial of Tesomet for hypothalamic obesity, at the 22nd European Congress of Endocrinology virtual annual meeting being held 5-9 September 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fleroxacin

            Therapeutic Area: Nutrition and Weight Loss Product Name: AM833

            Highest Development Status: Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 06, 2020

            Details:

            Novo Nordisk successfully completed the phase 3 programme with semaglutide 2.4 mg, the phase 2 trial with AM833 and the phase 1 combination trial with AM833 and semaglutide 2.4 mg, all in Obesity care.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IBI362

            Therapeutic Area: Nutrition and Weight Loss Product Name: IBI362

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 18, 2020

            Details:

            CIBI362B101 is a multiple-dose, safety and tolerability, pharmacokinetics and pharmacodynamics clinical study of IBI362 conducted in overweight or obese subjects in China.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fleroxacin

            Therapeutic Area: Nutrition and Weight Loss Product Name: AM833

            Highest Development Status: Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 18, 2020

            Details:

            The 26-week blinded phase 2 monotherapy trial with AM833 investigated safety, tolerability and efficacy for weight management in 706 people with obesity or overweight with at least one weight-related comorbidity.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BAM 15

            Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 05, 2020

            Details:

            Researcher at the Virginia Tech drug have recently identified a small mitochondrial uncoupler, named BAM15, that decreases the body fat mass of mice without affecting food intake and muscle mass or increasing body temperature.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Semaglutide

            Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 04, 2020

            Details:

            People treated with sc semaglutide 2.4 mg achieved a weight loss of 14.9%, from a mean baseline body weight of 105.3 kg, compared to a 2.4% weight loss with placebo. Weight loss sustained after 68 weeks of treatment, compared to 31.5% with placebo.

            National Institute on Aging

            • Development Update

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Disulfiram

            Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 14, 2020

            Details:

            Treatment with disulfiram, normally prescribed to treat alcohol use disorder, shows health benefits in animal study.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Semaglutide

            Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 13, 2020

            Details:

            Once-weekly semaglutide resulted in an average weight loss of 17.4% among people in a phase 3a trial, whereas those who received a dummy drug after a 20-week lead-in phase saw their body weight rebound by 6.9% during the rest 48 weeks.

            PharmaCompass